

Quick Start Guide

Here's how to log in to GlucosePATH.





Start Medicine Review

GlucosePATH makes it easy to see the data it uses for each medicine when making treatment decisions.





List of GlucosePATH Medicines

You can always review the data GlucosePATH uses for each medicine it knows about.

Click any medicine to see its data

GlucosePATH will also automatically display this screen when a change is made to a medication's data., so you're aware of the change and can review it.





Medicine Review

See the data GlucosePATH uses for each Type 2 Diabetes medicine.

Review the data

this screen shows the data GlucosePATH uses when it considers a medicine for a treatment regimen.

Metformin (Metformin)



I understand and accept the GlucosePATH information below regarding how Metformin is

ACCEPT & INCLUDE DECLINE & REMOVE used within GlucosePATH.

Selecting "Decline & Remove" will remove the medication from consideration in GlucosePATH

Details	History/Updates		
Dose:		Up to 2,550 m.g. per day	
Frequency:		Twice per day	
Macro Class:		Sensitizer	
Administration:		oral	
A1c reduction value displayed on FDA label:		0.4 - 1.4	
A1c reduction value used in GlucosePATH:		1.2	

GlucosePATH notes regarding a1c reduction value:

Table 3 of the FDA label shows an a1c reduction of 0.4 for Metformin as compared to glyburide and glyburide/Metformin combinations in a 29-week study (Metformin n=210). Because this 0.4 reduction is lower than the 1.4 reduction displayed on Metformin's FDA label, GlucosePATH uses a smaller value of 1.2 for Metformin's a1c reduction.

Yes

Side effects/Adverse reactions:

Listed on FDA Label (% of patients reporting)

Diarrhea (53.2)

Effect/Reaction is considered by GlucosePATH?



GlucosePATH will not use a medicine you decline in any patient recommendations.

If you accept the medicine, you'll be able to exclude it on a patient-by-patient basis later.

You can always return to this screen to review any medicine.

More data is below here

Including:

- Weight change
- Mechanism of Action
- Other medicines in this class
- Contraindications
- Link to FDA website for full label data

Explaining a decision

It is sometimes necessary to choose a default value for certain data. For example, the FDA label for metformin shows an HbA1c reduction of between 0.4 and 1.4. When GlucosePATH chooses a default value (1.2 here), the reasoning for that decision is given.

_∬ GlucosePATH



Get Recommendations

You're ready to see GlucosePATH make treatment suggestions.





Treatment suggestions

Patient Information Screen

This is the main work area for GlucosePATH. You'll probably spend most of your time here. For this step, just familiarize yourself with how the screen looks.

Patient data is on the left side of the screen

Place your mouse over any field's field represents.	heading to see what the				will be on the right side of the screen If you're using a phone or tablet
	مال PATH (GPU) PROFILE LOGO		PROFILE LOGOUT		with a small screen, treatment suggestions will appear at the bottom of the page
		N		•	
	St. Elizabeth Healthcare Patients Checked-In: O Patient ID: Age: Not Already Taking: Nothing selected Excluded Interventions:	Atc Level: ning selec Solution MUST contain: Nothing selected Drug Intolerance:	Waiting for input		
	Nothing selected • Forgot to Take: • Nothing selected • Susceptibility to Side Effects:	Nothing selected Comorbid: Nothing selected Sex:			
Display Solutions Click this button to start running GlucosePATH's analysis (in the next step).	Nothing selected	Male Female			Scroll down More patient data fields are found below here.
					6



Treatment Recommendations

GlucosePATH will recommend up to 10 distinct treatment regimens. Most regimens have different HbA1c, cost, weight change, or side-effect changes. Patients often find these options a helpful way to express their own treatment goals.

1 Solution Summary	_∬└PATH (GPU)	PROFILE LOGOUT	2 Medicine names are links Click on any medicine name to open a new browser window showing the Medicine	
This shows the patient's estimated out- of-pocket cost for this solution (\$185.00) along with the solution's overall score (95.4).			Review page you saw earlier.	
	St. Elizabeth Healthcare Patients Checked-In: 0			
Every option is rated using a 0-to-100 scoring system. Solutions with higher scores are shown first.	Patient ID: Q Age: Atc Level: 212345 Ø 43 8.1 Already Taking: Solution MUST contain: Ø Exercise, Glyburide (10 mg · Twt •) Ø Exercise	Demo-GERD Analyzed 70.470 solutions. Solution 1 [\$185.00 per month] Solution 1 has an overall score of 95.4 out of 100 PATH recommends these medicines: Exercise Invokana		
	Excluded interventions: Drug Intolerance: Diet Drug Intolerance: Forgot to Take: Comorbid: Nothing selected Migh LDL, Hypertension, Hyper. Gastroesophageal Reflux Disease Male Female	Metforminxr Oseni Prandin Coupons Invokana coupon from InvokanaCarePath.com Oseni sawings.card [+]Click here to view the basis for this recommendation including detailed data, scoring methodology, and including component scores	Want more detail? Click here to see every calculation used in GlucosePATH's recommendations, from estimated HbA1c levels, to weight change, cost, side effects, and more.	
Change the data! Scroll down until you see the <i>Maximum Solution</i>	DISPLAY SOLUTIONS State of Insurer: Kentucky Choose Insurer(s): Anthem Blue Cross and Blue Shield	Notes The patient's estimated untreated Alc level is 10.31 The estimated target Alc level for this solution is 6.63 4.0 Cost Sensitivity: This solution's total cost is \$185.00. Cost Sensitivity: The patient max cost is \$20.00.00. \$0 \$0 \$2,000.00	3 Estimated Outcomes The patient's estimated HbA1c, out-of- pocket cost, and weight change if following this regimen are displayed here.	
Cost field. Change it from 2000 to 50. Then click the Display Solutions button to see how GlucosePATH response.	Anthem Blue Cross and Blue Shield Choose Your Plan: Anthem Silver Pathway PPO 1750/305%/5500 - silver	Patient Out-of-Pocket Cost: \$185.00 System Cost: \$0.00 BMI: The patient's BMI is and this solution may result in may result in weight		
	Has Coupon For: Free Medications:	loss. Its weight loss effect estimate is (-3.0) on a scale from -10 (strong loss) to 10 (strong gain). strong loss	4 Potential Side Effects Potential side effects and reminders of contraindications are shown here.	
	Nothing selected Nothing selected	EXERCISE may help hypertigiyeridemia. EXERCISE can improve hypertension. INVOKANA can increase hypertension. INVOKANA can increase risk of yeast infections in women. METFORMING may have benefit in CAD.	7	

Advanced Features

Retrieve Patient Data

It's easy to retrieve data already entered into GlucosePATH.



Demo Scenarios

GlucosePATH comes with almost 30 different test scenarios. These are designed to show how GlucosePATH makes recommendations under a variety of conditions.



Scroll up to the top of the page and click the button labelled Display Solutions (shown on the previous slide of this Quick Start Guide).

Need help? Click here to see Frequently Asked

Questions or ask us to solve a problem. We'll respond via email or phone, whichever you prefer.

Demo Scenarios

Scenario Name	Designed to Illustrate
Alpha	A patient with high HbA1c levels and no other conditions. Shows PATH prescribing behavior in the simplest scenarios. The number in the label indicates the patient's HbA1c level, e.g., Alpha-6.5 demonstrates a patient with an HbA1c of 6.5.
BMI	A patient with HbA1c of 7.5, high BMI, and no other conditions. Shows PATH prescribing behavior when considering two factors. The number in the label indicates the patient's BMI, e.g., BMI-35 demonstrates a patient with a BMI of 35.
Cost	Demonstrates PATH prescribing behavior when patients express different sensitivity to the same cost. Cost Sensitivity refers to the financial burden the patient will face if the entire dollar amount shown in the Maximum Cost field is spent. The number in the label indicates the patient's cost sensitivity on a scale from 0 (not sensitive) to 10 (very sensitivity).
Demo-GERD	A patient with high LDL, hypertension, hypertriglyceridemia, and susceptibility to gastroesophageal reflux disease. Patient HbA1c is 8.1, BMI is 32, and is currently exercising, and taking glyburide and metformin. Demonstrates PATH's analysis in more complex scenarios where multiple constraints have to be considered.
Demo-Hypo	Similar to Demo-GERD, with hypoglycemia replacing GERD as the side effect to which the patient is susceptible.
Demo-Medi	The Demo-Hypo scenario, with a Medicare Part D insurance plan. (Not yet implemented.)
Demo-Rich	The Demo-Hypo scenario with a financially secure patient for whom treatment cost is not a consideration. Illustrates how PATH considers secondary drug effects, such as cardiovascular disease risk reduction, in its treatment decisions.
Resist	Similar to Alpha, with the additional constraint of patient insulin resistance. The number in the label indicates the patient's relative insulin resistance where 0 is no resistance and 10 is high resistance.
Secret	Similar to Resist, except it varies patient insulin secretion through beta cell function.

Score This Therapy

Allows you to choose a specific drug regimen and see how PATH scores it, for the patient data shown on the screen. Use it to answer questions such as "Why didn't PATH choose X?"



Manage Inventory (Optional)

The Inventory page keeps track of medicines available to patients.

